Citius Pharmaceuticals (CTXR) Other Operating Expenses (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Other Operating Expenses came in at $5.5 million in Q1 2026, up 103.87% YoY from $2.7 million in Q1 2025, and up 13.49% on a QoQ basis from $4.9 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Other Operating Expenses (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of Other Operating Expenses data on file, last reported at $5.5 million in Q1 2026.
- Quarterly Other Operating Expenses rose 103.87% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.0 million (up 46.13% YoY) and the FY2025 annual result came in at $10.8 million, down 8.47% from the prior year.
- Other Operating Expenses climbed to $5.5 million in Q1 2026, from $4.9 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $5.5 million in Q1 2026 to a low of $29571.0 in Q1 2022.
- A 5-year average of $2.4 million and a median of $2.7 million in 2025 frame the typical range for Other Operating Expenses.
- The widest YoY moves for Other Operating Expenses: up 11083.09% in 2022, down 66.94% in 2022.
- Tracing CTXR's Other Operating Expenses over 5 years: stood at $3.8 million in 2022, then retreated by 19.53% to $3.1 million in 2023, then decreased by 17.44% to $2.5 million in 2024, then soared by 92.24% to $4.9 million in 2025, then climbed by 13.49% to $5.5 million in 2026.
- The last three Other Operating Expenses figures came in at $5.5 million (Q1 2026), $4.9 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.51 Mn |
| Dec 31, 2025 | 4.85 Mn |
| Sep 30, 2025 | 2.89 Mn |
| Jun 30, 2025 | 2.72 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Sep 30, 2024 | 2.64 Mn |
| Jun 30, 2024 | 3.06 Mn |
| Mar 31, 2024 | 3.08 Mn |
| Dec 31, 2023 | 3.06 Mn |
| Sep 30, 2023 | 3.08 Mn |
| Jun 30, 2023 | 336,780.00 |
| Mar 31, 2023 | 303,275.00 |
| Dec 31, 2022 | 3.80 Mn |
| Sep 30, 2022 | 134,826.00 |
| Jun 30, 2022 | 53,020.00 |
| Mar 31, 2022 | 29,571.00 |
| Dec 31, 2021 | 33,982.00 |
| Sep 30, 2021 | 242,158.00 |
| Jun 30, 2021 | 160,398.00 |